Elevance Health (ELV) EBITDA (2009 - 2026)

Elevance Health (ELV) has 18 years of EBITDA data on file, last reported at $704.0 million in Q2 2026.

• On a quarterly basis, EBITDA rose 44.86% year-over-year to $704.0 million in Q2 2026; TTM through Jun 2026 was $2.6 billion, a 20.1% increase from a year earlier, with the FY2025 full-year figure at $2.2 billion, up 6.97% from the prior year.
• EBITDA for Q2 2026 stood at $704.0 million, down from $765.0 million in the prior quarter.
• Over the last five years, EBITDA for ELV reached as high as $765.0 million in Q1 2026 and fell as low as $360.0 million in Q1 2022.
• Historically, EBITDA has averaged $501.3 million across 5 years, with a median of $493.0 million in 2023.
• Across the five-year window, EBITDA retreated 6.45% in 2025 and jumped 44.86% in 2026, its largest moves.
• Year by year, EBITDA stood at $373.0 million in 2022, then jumped by 41.82% to $529.0 million in 2023, then decreased by 0.38% to $527.0 million in 2024, then fell by 6.45% to $493.0 million in 2025, then jumped by 42.8% to $704.0 million in 2026.
• Per Business Quant data, the three most recent EBITDA figures were $704.0 million in Q2 2026, $765.0 million in Q1 2026, and $493.0 million in Q4 2025.